Company Encyclopedia
View More
name
Anti-Pandemic Concept
CP00007.US
News
View More

Stance Capital LLC Takes Position in Gilead Sciences, Inc. $GILD

Stance Capital LLC acquired 11,825 shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, valued at approximately $1,311,000. Other hedge funds also increased their positions in Gilead Sciences. The company's stock opened at $120.40 on Friday, with a 52-week range of $88.57 to $128.70. Gilead Sciences reported quarterly earnings of $2.47 per share, beating estimates, and announced a quarterly dividend of $0.79 per share. Insiders sold 135,757 shares valued at $16,616,127 last quarter. Analysts forecast growth for Gilead Sciences.

Market Beat·
US
GILD
-2.28%
Market Beat·
US
GILD
-2.28%

Key facts: Abbott Laboratories appoints Nita Ahuja to Board; VP reports share gift

On December 12, 2025, Abbott Laboratories appointed Nita Ahuja, M.D. to its Board of Directors.1On December 12, 2025, Daniel Gesua Sive Salvadori, Vice President of Abbott Laboratories, reported a gift of 1,536 shares through a Form 4 filing, bringing his total direct holdings to 132,233 shares.2

TradingView·
US
ABT
+1.77%
TradingView·
US
ABT
+1.77%

Why Arcus Biosciences (RCUS) Is Down 15.4% After Ending Key Gastric Cancer Trial And Pivoting Pipeline

Arcus Biosciences, along with Gilead Sciences, has halted the Phase 3 STAR-221 trial after interim results showed no survival benefit in gastric and esophageal cancers. The company will now focus on its HIF-2α inhibitor, casdatifan, and other small-molecule programs. This shift alters Arcus's investment narrative, emphasizing casdatifan's potential in renal cell carcinoma and increasing execution risks. The company's development plan targets multiple RCC readouts by 2026-2027, with projected revenue of $327.1 million by 2028, requiring a 7.7% annual growth.

Simplywall·
US
GILD
-2.28%
US
RCUS
-14.36%
Simplywall·
US
GILD
-2.28%
US
RCUS
-14.36%

Gilead (GILD) Valuation Check as New Yescarta Data Reinforces CAR T Role in Second-Line Lymphoma

Gilead Sciences' CAR T therapy Yescarta shows consistent benefits for large B cell lymphoma, boosting investor confidence. Despite recent share price fluctuations, Gilead's long-term momentum remains strong, with shares trading at $120.40, undervalued against a fair value of $130.63. Analysts have mixed price targets, ranging from $98.0 to $143.0. The narrative suggests upside potential driven by HIV and oncology cash flows, but warns of risks from policy pricing pressures and program setbacks. Investors are encouraged to explore other undervalued stocks and AI penny stocks for potential opportunities.

Simplywall·
US
GILD
-2.28%
Simplywall·
US
GILD
-2.28%

West Pharmaceutical Services Inc. Stock Underperforms Friday When Compared To Competitors

West Pharmaceutical Services Inc. stock fell 1.83% to $267.56 on Friday, underperforming compared to competitors like Abbott Laboratories, Becton Dickinson & Co., and Baxter International Inc., which saw gains. The stock is 23.31% below its 52-week high. Trading volume exceeded the 50-day average. The S&P 500 and Dow Jones also fell during the session.

Dow Jones·
US
WST
-1.83%
US
BAX
+1.32%
US
ABT
+1.77%
Dow Jones·
US
WST
-1.83%
US
BAX
+1.32%
US
ABT
+1.77%
Posts
View More

Intel's CY26 capex to remain nearly flat. More optimistic than previous guidance of above maintenance and $16B. Next year capex will be for 2027 capacity. Around which time Intel's external foundry bu............

  • 0
© 2025 Longbridge｜Disclaimer